Breaking the Fall Off the Patent Cliff: Can Developing Countries Help Big Pharma?

Expiring patents are expected to contribute billions of dollars towards the loss of revenue of drug manufacturers in the years to come. To save itself from falling off the patent cliff, Big Pharma needs to restock its R&D shelves in a cost-effective manner. Aside from developing niche products like biologics and acquiring companies with promising drugs […]

Paying for Delay: Old School Lawyering Meets Compound Interest

Compound interest ought to be the rule rather than the exception in calculating prejudgment interest in litigation involving commercial businesses. It is welcoming to see recognition and expansion of this concept in patent litigation.

A Dose of Consistency: SCOTUS Settles the Controversy in Teva v Sandoz for Patent Litigation

In Teva Pharmaceuticals USA Inc  v Sandoz Inc, a patent infringement case evolved into an opportunity for the Supreme Court of the United States (SCOTUS) to settle a decades-long controversy regarding how the Federal Circuit should review patent construction claims. By convention, the Federal Circuit has reviewed such claims de novo, ignoring Rule 52(a) of […]